Kairos Pharma entered into an Investigator/Institution Initiated Research Support Agreement with Bayer to obtain radium for a study evaluating radium with ENV-105 (carotuximab) in models of prostate cancer bone metastasis. Kairos will initiate, manage, and finance the study, and must secure Bayer's…
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, i…
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and equity plan amendments. All proposals were approved by stockholders, with final results to be filed with the SEC. Stockholders were invited to submit questions.Based on Kairos Pharma, Lt…
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and equity plan amendments, all of which were approved by stockholders. A quorum was established, and final voting results will be filed with the SEC. Stockholders were invited to submit que…
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and an equity plan amendment, all of which were approved by stockholders. A quorum was established, and final voting results will be filed with the SEC.Based on Kairos Pharma, Ltd. [KAPA] AG…
